Dr. Stephen Nicholls, MBBS

Dr. Stephen Nicholls is an Australian cardiologist based in Clayton, Melbourne. He is the inaugural Director of the Victorian Heart Institute and a Professor of Cardiology at Monash University, and he is Program Director of the Victorian Heart Hospital, MonashHeart and Intensive Care at Monash Health. He was appointed director of MonashHeart and professor of cardiology at Monash University in October 2018 (https://en.wikipedia.org/wiki/Stephen_Nicholls).

He works as a preventive cardiologist. His stated clinical interest is finding heart disease risk earlier and preventing cardiovascular events, and his institutional profile says he focuses on improving fairness in risk and treatment, including women's heart health and other under-served groups (https://www.monash.edu/vic-heart-institute/about/operational-leadership-team).

He trained in cardiology at John Hunter Hospital and earned a PhD in Medical Biochemistry at the University of Adelaide, with a thesis on high density lipoproteins and protection against atherosclerosis (https://www.radcliffecardiology.com/authors/stephen-nicholls). He has previously worked at the University of Adelaide, Cleveland Clinic and SAHMRI (https://en.wikipedia.org/wiki/Stephen_Nicholls). He served as President of the Cardiac Society of Australia and New Zealand from 2022 to 2024 (https://www.heartlungcirc.org/article/S1443-9506(22)01015-0/abstract).

Much of his public profile comes from research. Monash lists more than 770 manuscripts, book chapters and conference proceedings and more than $100 million in research funding (https://research.monash.edu/en/persons/stephen-nicholls/). He led the STRENGTH trial of high-dose omega-3 fatty acids published in JAMA in 2020 (https://www.tctmd.com/news/fish-oil-tanks-strength-making-waves-reduce-it) and is among the authors of the Phase 3 BROADWAY trial of the cholesterol drug obicetrapib (https://www.alzforum.org/therapeutics/obicetrapib). No Open Payments data applies, as he practises in Australia.